Outset Medical (OM) Stock Forecast & Price Target

Outset Medical Inc demonstrates a strong financial outlook driven by stability in its salesforce, an expanding deal pipeline, and the anticipated launch of a new product, which collectively contribute to growing recurring revenue and improved margins. The company reported a gross margin of 42.9%, exceeding consensus expectations, and continues to target high-30s gross margins for FY25, positioning it favorably for achieving its long-term goal of 50%. Additionally, with a commitment to reducing operating expenses and a projected cash burn of under $50 million for 2025, Outset Medical is set to enhance its financial sustainability and operational efficiency.

The negative outlook on Outset Medical's stock is primarily driven by ongoing delays in enterprise deal timing, leading to a reduction in full-year revenue guidance by approximately $7 million at the midpoint. The company's Q3 results revealed a notable sales miss, particularly in consumables revenue, which contributed to total revenues of $29.4 million falling short of consensus expectations. Additionally, the disconnect between consumables utilization and revenue orders among key customers signals potential underlying issues in demand, further exacerbating concerns about future financial performance.